Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Efficacy of the oral nucleoside prodrug GS-5245 (Obeldesivir) against SARS-CoV-2 and coronaviruses with pandemic potential.

Autor: Martinez DR; Department of Immunobiology, Yale School of Medicine, New Haven, CT, 06510, USA.; Yale Center for Infection and Immunity, Yale School of Medicine, New Haven, CT, 06510, USA., Moreira FR; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Zweigart MR; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Gully KL; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., De la Cruz G; Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC, USA., Brown AJ; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Adams LE; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Catanzaro N; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Yount B; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Baric TJ; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Mallory ML; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Conrad H; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., May SR; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Dong S; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Scobey DT; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Montgomery SA; Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA., Perry J; Gilead Sciences, Inc, Foster City, CA, USA., Babusis D; Gilead Sciences, Inc, Foster City, CA, USA., Barrett KT; Gilead Sciences, Inc, Foster City, CA, USA., Nguyen AH; Gilead Sciences, Inc, Foster City, CA, USA., Nguyen AQ; Gilead Sciences, Inc, Foster City, CA, USA., Kalla R; Gilead Sciences, Inc, Foster City, CA, USA., Bannister R; Gilead Sciences, Inc, Foster City, CA, USA., Bilello JP; Gilead Sciences, Inc, Foster City, CA, USA., Feng JY; Gilead Sciences, Inc, Foster City, CA, USA., Cihlar T; Gilead Sciences, Inc, Foster City, CA, USA., Baric RS; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; Rapidly Emerging Antiviral Drug Development Initiative, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Mackman RL; Gilead Sciences, Inc, Foster City, CA, USA., Schäfer A; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; Rapidly Emerging Antiviral Drug Development Initiative, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Sheahan TP; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; Rapidly Emerging Antiviral Drug Development Initiative, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Publikováno v: BioRxiv : the preprint server for biology [bioRxiv] 2023 Jun 28. Date of Electronic Publication: 2023 Jun 28.